Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 4/2007

01.04.2007 | Original Article

Regulation of galectin-1 expression by transforming growth factor β1 in metastatic mammary adenocarcinoma cells: implications for tumor-immune escape

verfasst von: Cecilia M. Daroqui, Juan M. Ilarregui, Natalia Rubinstein, Mariana Salatino, Marta A. Toscano, Paula Vazquez, Andrei Bakin, Lydia Puricelli, Elisa Bal de Kier Joffé, Gabriel A. Rabinovich

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 4/2007

Einloggen, um Zugang zu erhalten

Abstract

Tumors escape from immune surveillance by producing immunosuppressive cytokines and proapototic factors, including TGF-β and galectin-1 (Gal-1). Since immunosuppressive mechanisms might act in concert to confer tumor-immune privilege, we investigated the potential cross talk between TGF-β and Gal-1 in highly metastatic mammary adenocarcinoma (LM3) cells. While Gal-1 treatment was not capable of regulating TGF-β synthesis, a pronounced and dose-dependent increase in Gal-1 expression was observed when tumor cells were treated with TGF-β1. This effect was also observed in the murine lung adenocarcinoma LP07 and in the human breast adenocarcinoma MCF-7 cell lines. TGF-β1-mediated upregulation of Gal-1 expression was specifically mediated by TβRI and TβRII, since it was abrogated when LM3 cells were infected with retroviral vectors expressing the dominant negative forms of these receptors. In addition, gal-1 gene sequence analysis revealed the presence of three putative binding sites for Smad4 and Smad3 transcription factors, consistent with the ability of TGF-β1 to trigger a Smad-dependent signaling pathway in these cells. Thus, TGF-β1 may trigger a Smad-dependent pathway to control Gal-1 expression, suggesting that distinct mechanisms might cooperate in tilting the balance toward an immunosuppressive environment at the tumor site.
Literatur
1.
Zurück zum Zitat Akhurst RJ, Derynck R (2001) TGF-beta signaling in cancer—a double-edged sword. Trends Cell Biol 11:S44–S51PubMed Akhurst RJ, Derynck R (2001) TGF-beta signaling in cancer—a double-edged sword. Trends Cell Biol 11:S44–S51PubMed
2.
Zurück zum Zitat Bakin AV, Rinehart C, Tomlinson AK, Arteaga CL (2002) p38 mitogen-activated protein kinase is required for TGF β-mediated fibroblastic transdifferentiation and cell migration. J Cell Sci 115:3193–3206PubMed Bakin AV, Rinehart C, Tomlinson AK, Arteaga CL (2002) p38 mitogen-activated protein kinase is required for TGF β-mediated fibroblastic transdifferentiation and cell migration. J Cell Sci 115:3193–3206PubMed
3.
Zurück zum Zitat Brooks SC, Locke ER, Soule HD (1973) Estrogen receptor in a human cell line (MCF-7) from breast carcinoma. J Biol Chem 248:6251–6253PubMed Brooks SC, Locke ER, Soule HD (1973) Estrogen receptor in a human cell line (MCF-7) from breast carcinoma. J Biol Chem 248:6251–6253PubMed
4.
Zurück zum Zitat Camby I, Belot N, Lefranc F, Sadeghi N, de Launoit Y, Kaltner H, Musette S, Darro F, Danguy A, Salmon I, Gabius HJ, Kiss R (2002) Galectin-1 modulates human glioblastoma cell migration into the brain through modifications to the actin cytoskeleton and levels of expression of small GTPases. J Neuropathol Exp Neurol 61:585–596PubMed Camby I, Belot N, Lefranc F, Sadeghi N, de Launoit Y, Kaltner H, Musette S, Darro F, Danguy A, Salmon I, Gabius HJ, Kiss R (2002) Galectin-1 modulates human glioblastoma cell migration into the brain through modifications to the actin cytoskeleton and levels of expression of small GTPases. J Neuropathol Exp Neurol 61:585–596PubMed
5.
Zurück zum Zitat Camby I, Decaestecker C, Lefranc F, Kaltner H, Gabius HJ, Kiss R (2005) Galectin-1 knocking down in human U87 glioblastoma cells alters their gene expression pattern. Biochem Biophys Res Commun 335:27–35PubMedCrossRef Camby I, Decaestecker C, Lefranc F, Kaltner H, Gabius HJ, Kiss R (2005) Galectin-1 knocking down in human U87 glioblastoma cells alters their gene expression pattern. Biochem Biophys Res Commun 335:27–35PubMedCrossRef
6.
Zurück zum Zitat Chiariotti L, Benvenuto G, Salvatore P, Veneziani BM, Villone G, Fusco A, Russo T, Bruni CB (1994) Expression of the soluble lectin L-14 gene is induced by TSH in thyroid cells and suppressed by retinoic acid in transformed neural cells. Biochem Biophys Res Commun 199:540–546PubMedCrossRef Chiariotti L, Benvenuto G, Salvatore P, Veneziani BM, Villone G, Fusco A, Russo T, Bruni CB (1994) Expression of the soluble lectin L-14 gene is induced by TSH in thyroid cells and suppressed by retinoic acid in transformed neural cells. Biochem Biophys Res Commun 199:540–546PubMedCrossRef
7.
Zurück zum Zitat Chiariotti L, Salvatore P, Frunzio R, Bruni CB (2004) Galectin genes: regulation of expression. Glycoconj J 19:441–449PubMedCrossRef Chiariotti L, Salvatore P, Frunzio R, Bruni CB (2004) Galectin genes: regulation of expression. Glycoconj J 19:441–449PubMedCrossRef
8.
Zurück zum Zitat Cooper DN (2002) Galectinomics: finding themes in complexity. Biochim Biophys Acta 1572:209–231PubMed Cooper DN (2002) Galectinomics: finding themes in complexity. Biochim Biophys Acta 1572:209–231PubMed
9.
Zurück zum Zitat Danguy A, Camby I, Kiss R (2002) Galectins and cancer. Biochim Biophys Acta 1572:285–293PubMed Danguy A, Camby I, Kiss R (2002) Galectins and cancer. Biochim Biophys Acta 1572:285–293PubMed
10.
Zurück zum Zitat Daroqui MC, Puricelli LI, Urtreger AJ, Elizalde PV, Lanuza GM, Bal de Kier Joffe E (2003) Involvement of TGF-beta(s)/T(beta)Rs system in tumor progression of murine mammary adenocarcinomas. Breast Cancer Res Treat 80:287–301PubMedCrossRef Daroqui MC, Puricelli LI, Urtreger AJ, Elizalde PV, Lanuza GM, Bal de Kier Joffe E (2003) Involvement of TGF-beta(s)/T(beta)Rs system in tumor progression of murine mammary adenocarcinomas. Breast Cancer Res Treat 80:287–301PubMedCrossRef
11.
Zurück zum Zitat Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21:137–148PubMedCrossRef Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21:137–148PubMedCrossRef
12.
Zurück zum Zitat Gabrilovich D, Pisarev V (2003) Tumor escape from immune response: mechanisms and targets of activity. Curr Drug Targets 4:525–536PubMedCrossRef Gabrilovich D, Pisarev V (2003) Tumor escape from immune response: mechanisms and targets of activity. Curr Drug Targets 4:525–536PubMedCrossRef
13.
Zurück zum Zitat Gillenwater A, Xu XC, Estrov Y, Sacks PG, Lotan D, Lotan R (1998) Modulation of galectin-1 content in human head and neck squamous carcinoma cells by sodium butyrate. Int J Cancer 75:217–224PubMedCrossRef Gillenwater A, Xu XC, Estrov Y, Sacks PG, Lotan D, Lotan R (1998) Modulation of galectin-1 content in human head and neck squamous carcinoma cells by sodium butyrate. Int J Cancer 75:217–224PubMedCrossRef
14.
Zurück zum Zitat Gorelik L, Flavell RA (2001) Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 7:1118–1122PubMedCrossRef Gorelik L, Flavell RA (2001) Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 7:1118–1122PubMedCrossRef
15.
Zurück zum Zitat Hirabayashi J, Hashidate T, Arata Y, Nishi N, Nakamura T, Hirashima M, Urashima T, Oka T, Futai M, Muller WE, Yagi F, Kasai K (2002) Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. Biochim Biophys Acta 1572:232–254PubMed Hirabayashi J, Hashidate T, Arata Y, Nishi N, Nakamura T, Hirashima M, Urashima T, Oka T, Futai M, Muller WE, Yagi F, Kasai K (2002) Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. Biochim Biophys Acta 1572:232–254PubMed
16.
Zurück zum Zitat Kaklamani VG, Pasche B (2004) Role of TGF-beta in cancer and the potential for therapy and prevention. Expert Rev Anticancer Ther 4:649–661PubMedCrossRef Kaklamani VG, Pasche B (2004) Role of TGF-beta in cancer and the potential for therapy and prevention. Expert Rev Anticancer Ther 4:649–661PubMedCrossRef
17.
Zurück zum Zitat Kloth JN, Fleuren GJ, Oosting J, de Menezes RX, Eilers PH, Kenter GG, Gorter A (2005) Substantial changes in gene expression of Wnt, MAPK and TNFalpha pathways induced by TGF-beta1 in cervical cancer cell lines. Carcinogenesis 26:1493–1502PubMedCrossRef Kloth JN, Fleuren GJ, Oosting J, de Menezes RX, Eilers PH, Kenter GG, Gorter A (2005) Substantial changes in gene expression of Wnt, MAPK and TNFalpha pathways induced by TGF-beta1 in cervical cancer cell lines. Carcinogenesis 26:1493–1502PubMedCrossRef
18.
Zurück zum Zitat Kopitz J, von Reitzenstein C, Andre S, Kaltner H, Uhl J, Ehemann V, Cantz M, Gabius HJ (2001) Negative regulation of neuroblastoma cell growth by carbohydrate-dependent surface binding of galectin-1 and functional divergence from galectin-3. J Biol Chem 276:35917–35923PubMedCrossRef Kopitz J, von Reitzenstein C, Andre S, Kaltner H, Uhl J, Ehemann V, Cantz M, Gabius HJ (2001) Negative regulation of neuroblastoma cell growth by carbohydrate-dependent surface binding of galectin-1 and functional divergence from galectin-3. J Biol Chem 276:35917–35923PubMedCrossRef
19.
Zurück zum Zitat Lahm H, Andre S, Hoeflich A, Kaltner H, Siebert HC, Sordat B, von der Lieth CW, Wolf E, Gabius HJ (2004) Tumor galectinology: insights into the complex network of a family of endogenous lectins. Glycoconj J 20:227–238PubMedCrossRef Lahm H, Andre S, Hoeflich A, Kaltner H, Siebert HC, Sordat B, von der Lieth CW, Wolf E, Gabius HJ (2004) Tumor galectinology: insights into the complex network of a family of endogenous lectins. Glycoconj J 20:227–238PubMedCrossRef
20.
Zurück zum Zitat Laping NJ, Grygielko E, Mathur A, Butter S, Bomberger J, Tweed C, Martin W, Fornwald J, Lehr R, Harling J, Gaster L, Callahan JF, Olson BA (2002) Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Mol Pharmacol 62:58–64PubMedCrossRef Laping NJ, Grygielko E, Mathur A, Butter S, Bomberger J, Tweed C, Martin W, Fornwald J, Lehr R, Harling J, Gaster L, Callahan JF, Olson BA (2002) Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Mol Pharmacol 62:58–64PubMedCrossRef
21.
Zurück zum Zitat Le QT, Shi G, Cao H, Nelson DW, Wang Y, Chen EY, Zhao S, Kong C, Richardson D, O’Byrne KJ, Giaccia AJ, Koong AC (2005) Galectin-1: a link between tumor hypoxia and tumor immune privilege. J Clin Oncol 23:8932–8941PubMedCrossRef Le QT, Shi G, Cao H, Nelson DW, Wang Y, Chen EY, Zhao S, Kong C, Richardson D, O’Byrne KJ, Giaccia AJ, Koong AC (2005) Galectin-1: a link between tumor hypoxia and tumor immune privilege. J Clin Oncol 23:8932–8941PubMedCrossRef
22.
Zurück zum Zitat Levy L, Hill CS (2005) Smad4 dependency defines two classes of transforming growth factor {beta} (TGF-{beta}) target genes and distinguishes TGF-{beta}-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses. Mol Cell Biol 25:8108–8125PubMedCrossRef Levy L, Hill CS (2005) Smad4 dependency defines two classes of transforming growth factor {beta} (TGF-{beta}) target genes and distinguishes TGF-{beta}-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses. Mol Cell Biol 25:8108–8125PubMedCrossRef
23.
Zurück zum Zitat Liu F, Rabinovich G (2005) Galectins as modulators of tumour progression. Nature Rev Cancer 5:29–41CrossRef Liu F, Rabinovich G (2005) Galectins as modulators of tumour progression. Nature Rev Cancer 5:29–41CrossRef
24.
Zurück zum Zitat Lu Y, Lotan D, Lotan R (2000) Differential regulation of constitutive and retinoic acid-induced galectin-1 gene transcription in murine embryonal carcinoma and myoblastic cells. Biochim Biophys Acta 1491:13–9PubMed Lu Y, Lotan D, Lotan R (2000) Differential regulation of constitutive and retinoic acid-induced galectin-1 gene transcription in murine embryonal carcinoma and myoblastic cells. Biochim Biophys Acta 1491:13–9PubMed
26.
Zurück zum Zitat Mendez R, Ruiz-Cabello F, Rodriguez T, Del Campo A, Paschen A, Schadendorf D, Garrido F (2006) Identification of different tumor escape mechanisms in several metastases from a melanoma patient undergoing immunotherapy. Cancer Immunol Immunother (Epub ahead of print) Mendez R, Ruiz-Cabello F, Rodriguez T, Del Campo A, Paschen A, Schadendorf D, Garrido F (2006) Identification of different tumor escape mechanisms in several metastases from a melanoma patient undergoing immunotherapy. Cancer Immunol Immunother (Epub ahead of print)
27.
Zurück zum Zitat Michl P, Ramjaun AR, Pardo OE, Warne PH, Wagner M, Poulsom R, D’Arrigo C, Ryder K, Menke A, Gress T, Downward J (2005) CUTL1 is a target of TGF(beta) signaling that enhances cancer cell motility and invasiveness. Cancer Cell 7:521–532PubMedCrossRef Michl P, Ramjaun AR, Pardo OE, Warne PH, Wagner M, Poulsom R, D’Arrigo C, Ryder K, Menke A, Gress T, Downward J (2005) CUTL1 is a target of TGF(beta) signaling that enhances cancer cell motility and invasiveness. Cancer Cell 7:521–532PubMedCrossRef
28.
Zurück zum Zitat Moiseeva EP, Javed Q, Spring EL, de Bono DP (2000) Galectin-1 is involved in vascular smooth muscle cell proliferation. Cardiovasc Res 45:493–502PubMedCrossRef Moiseeva EP, Javed Q, Spring EL, de Bono DP (2000) Galectin-1 is involved in vascular smooth muscle cell proliferation. Cardiovasc Res 45:493–502PubMedCrossRef
29.
Zurück zum Zitat Oft M, Heider KH, Beug H (1998) TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol 8:1243–52PubMedCrossRef Oft M, Heider KH, Beug H (1998) TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol 8:1243–52PubMedCrossRef
30.
31.
Zurück zum Zitat Pardoll D, Allison J (2004) Cancer immunotherapy: breaking the barriers to harvest the crop. Nat Med 10:887–892PubMedCrossRef Pardoll D, Allison J (2004) Cancer immunotherapy: breaking the barriers to harvest the crop. Nat Med 10:887–892PubMedCrossRef
32.
Zurück zum Zitat Pawelec G (1999) Tumour escape from the immune response: the last hurdle for successful immunotherapy of cancer? Cancer Immunol Immunother 48:343–345PubMedCrossRef Pawelec G (1999) Tumour escape from the immune response: the last hurdle for successful immunotherapy of cancer? Cancer Immunol Immunother 48:343–345PubMedCrossRef
33.
Zurück zum Zitat Paz A, Haklai R, Elad-Sfadia G, Ballan E, Kloog Y (2001) Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation. Oncogene 20:7486–7493PubMedCrossRef Paz A, Haklai R, Elad-Sfadia G, Ballan E, Kloog Y (2001) Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation. Oncogene 20:7486–7493PubMedCrossRef
34.
Zurück zum Zitat Rabinovich GA, Daly G, Dreja H, Tailor H, Riera CM, Hirabayashi J, Chernajovsky Y (1999) Recombinant galectin-1 and its genetic delivery suppress collagen-induced arthritis via T cell apoptosis. J Exp Med 190:385–398PubMedCrossRef Rabinovich GA, Daly G, Dreja H, Tailor H, Riera CM, Hirabayashi J, Chernajovsky Y (1999) Recombinant galectin-1 and its genetic delivery suppress collagen-induced arthritis via T cell apoptosis. J Exp Med 190:385–398PubMedCrossRef
35.
Zurück zum Zitat Rabinovich GA, Baum LG, Tinari N, Paganelli R, Natoli C, Liu FT, Iacobelli S (2002) Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response? Trends Immunol 23:313–320PubMedCrossRef Rabinovich GA, Baum LG, Tinari N, Paganelli R, Natoli C, Liu FT, Iacobelli S (2002) Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response? Trends Immunol 23:313–320PubMedCrossRef
36.
Zurück zum Zitat Rabinovich GA, Rubinstein N, Matar P, Rozados V, Gervasoni S, Scharovsky GO (2002) The antimetastatic effect of a single low dose of cyclophosphamide involves modulation of galectin-1 and Bcl-2 expression. Cancer Immunol Immunother 50:597–603PubMedCrossRef Rabinovich GA, Rubinstein N, Matar P, Rozados V, Gervasoni S, Scharovsky GO (2002) The antimetastatic effect of a single low dose of cyclophosphamide involves modulation of galectin-1 and Bcl-2 expression. Cancer Immunol Immunother 50:597–603PubMedCrossRef
37.
Zurück zum Zitat Rabinovich GA, Rubinstein N, Toscano MA (2002) Role of galectins in inflammatory and immunomodulatory processes. Biochim Biophys Acta 1572:274–284PubMed Rabinovich GA, Rubinstein N, Toscano MA (2002) Role of galectins in inflammatory and immunomodulatory processes. Biochim Biophys Acta 1572:274–284PubMed
38.
Zurück zum Zitat Rabinovich GA, Cumashi A, Bianco GA, Ciavardelli D, Iurisci I, D’Egidio M, Piccolo E, Tinari N, Nifantiev N, Iacobelli S (2006) Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis. Glycobiology 16:210–220PubMedCrossRef Rabinovich GA, Cumashi A, Bianco GA, Ciavardelli D, Iurisci I, D’Egidio M, Piccolo E, Tinari N, Nifantiev N, Iacobelli S (2006) Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis. Glycobiology 16:210–220PubMedCrossRef
39.
Zurück zum Zitat Real LM, Jimenez P, Kirkin A, Serrano A, Garcia A, Canton J, Zeuthen J, Garrido F, Ruiz-Cabello F (2001) Multiple mechanisms of immune evasion can coexist in melanoma tumor cell lines derived from the same patient. Cancer Immunol Immunother 49:621–628PubMedCrossRef Real LM, Jimenez P, Kirkin A, Serrano A, Garcia A, Canton J, Zeuthen J, Garrido F, Ruiz-Cabello F (2001) Multiple mechanisms of immune evasion can coexist in melanoma tumor cell lines derived from the same patient. Cancer Immunol Immunother 49:621–628PubMedCrossRef
40.
Zurück zum Zitat Rubinstein N, Alvarez M, Zwirner NW, Toscano MA, Ilarregui JM, Bravo A, Mordoh J, Fainboim L, Podhajcer OL, Rabinovich GA (2004) Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell 5:241–251PubMedCrossRef Rubinstein N, Alvarez M, Zwirner NW, Toscano MA, Ilarregui JM, Bravo A, Mordoh J, Fainboim L, Podhajcer OL, Rabinovich GA (2004) Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell 5:241–251PubMedCrossRef
41.
Zurück zum Zitat Satterwhite DJ, Matsunami N, White RL (2000) TGF-beta1 inhibits BRCA1 expression through a pathway that requires pRb. Biochem Biophys Res Commun 276:686–692PubMedCrossRef Satterwhite DJ, Matsunami N, White RL (2000) TGF-beta1 inhibits BRCA1 expression through a pathway that requires pRb. Biochem Biophys Res Commun 276:686–692PubMedCrossRef
42.
Zurück zum Zitat Sorme P, Kahl-Knutsson B, Wellmar U, Magnusson BG, Leffler H, Nilsson UJ (2003) Design and synthesis of galectin inhibitors. Methods Enzymol 363: 157–169PubMedCrossRef Sorme P, Kahl-Knutsson B, Wellmar U, Magnusson BG, Leffler H, Nilsson UJ (2003) Design and synthesis of galectin inhibitors. Methods Enzymol 363: 157–169PubMedCrossRef
43.
Zurück zum Zitat ten Dijke P, Hill CS (2004) New insights into TGF-beta-Smad signalling. Trends Biochem Sci 29:265–273PubMedCrossRef ten Dijke P, Hill CS (2004) New insights into TGF-beta-Smad signalling. Trends Biochem Sci 29:265–273PubMedCrossRef
44.
Zurück zum Zitat Thomas DA, Massague J (2005) TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8:369–380PubMedCrossRef Thomas DA, Massague J (2005) TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8:369–380PubMedCrossRef
45.
Zurück zum Zitat Tinari N, Kuwabara I, Huflejt ME, Shen PF, Iacobelli S, Liu FT (2001) Glycoprotein 90K/MAC-2BP interacts with galectin-1 and mediates galectin-1-induced cell aggregation. Int J Cancer 91:167–172PubMedCrossRef Tinari N, Kuwabara I, Huflejt ME, Shen PF, Iacobelli S, Liu FT (2001) Glycoprotein 90K/MAC-2BP interacts with galectin-1 and mediates galectin-1-induced cell aggregation. Int J Cancer 91:167–172PubMedCrossRef
46.
Zurück zum Zitat Urtreger AJ, Diament MJ, Ranuncolo SM, Del C Vidal M, Puricelli LI, Klein SM, Bal de Kier Joffe ED (2001) New murine cell line derived from a spontaneous lung tumor induces paraneoplastic syndromes. Int J Oncol 18:639–647PubMed Urtreger AJ, Diament MJ, Ranuncolo SM, Del C Vidal M, Puricelli LI, Klein SM, Bal de Kier Joffe ED (2001) New murine cell line derived from a spontaneous lung tumor induces paraneoplastic syndromes. Int J Oncol 18:639–647PubMed
47.
Zurück zum Zitat Urtreger A, Ladeda V, Puricelli L, Rivelli A, Vidal MC, Lustig ES, Bal de Kier Joffé E (1997) Modulation of fibronectin expression and proteolytic activity associated with the invasive and metastatic phenotype in two murine mammary cell lines. Int J Oncol 11:489–496 Urtreger A, Ladeda V, Puricelli L, Rivelli A, Vidal MC, Lustig ES, Bal de Kier Joffé E (1997) Modulation of fibronectin expression and proteolytic activity associated with the invasive and metastatic phenotype in two murine mammary cell lines. Int J Oncol 11:489–496
48.
Zurück zum Zitat van den Brule F, Califice S, Castronovo V (2004) Expression of galectins in cancer: a critical review. Glycoconj J 19:537–542PubMedCrossRef van den Brule F, Califice S, Castronovo V (2004) Expression of galectins in cancer: a critical review. Glycoconj J 19:537–542PubMedCrossRef
49.
Zurück zum Zitat van den Brule FA, Buicu C, Baldet M, Sobel ME, Cooper DN, Marschal P, Castronovo V (1995) Galectin-1 modulates human melanoma cell adhesion to laminin. Biochem Biophys Res Commun 209:760–767PubMedCrossRef van den Brule FA, Buicu C, Baldet M, Sobel ME, Cooper DN, Marschal P, Castronovo V (1995) Galectin-1 modulates human melanoma cell adhesion to laminin. Biochem Biophys Res Commun 209:760–767PubMedCrossRef
50.
Zurück zum Zitat Zacarias-Fluck MF, Rico MJ, Gervasoni SI, Ilarregui JM, Toscano MA, Rabinovich GA, Scharovsky GO (2006) Low dose cyclophosphamide modulates galectin-1 expression and function in an experimental rat lymphoma model. Cancer Immunol Immunother (Epub ahead of print) Zacarias-Fluck MF, Rico MJ, Gervasoni SI, Ilarregui JM, Toscano MA, Rabinovich GA, Scharovsky GO (2006) Low dose cyclophosphamide modulates galectin-1 expression and function in an experimental rat lymphoma model. Cancer Immunol Immunother (Epub ahead of print)
Metadaten
Titel
Regulation of galectin-1 expression by transforming growth factor β1 in metastatic mammary adenocarcinoma cells: implications for tumor-immune escape
verfasst von
Cecilia M. Daroqui
Juan M. Ilarregui
Natalia Rubinstein
Mariana Salatino
Marta A. Toscano
Paula Vazquez
Andrei Bakin
Lydia Puricelli
Elisa Bal de Kier Joffé
Gabriel A. Rabinovich
Publikationsdatum
01.04.2007
Verlag
Springer-Verlag
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 4/2007
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-006-0208-9

Weitere Artikel der Ausgabe 4/2007

Cancer Immunology, Immunotherapy 4/2007 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.